Brands

Features

Oral JAK inhibitors unlikely to be totally shut out in eczema by black box warning

Dermatologists point to several uptake openings for JAK inhibitors in moderate-to-severe eczema despite highly publicized side effect concerns.

Reynald Castañeda

Features

Regulatory roundup: Novartis rare disease drug sees approval chances rise after trial completes

Features

Regulatory roundup: BMS’s T lymphocyte immunotherapy tripped by lung cancer trial termination

Features

Regulatory roundup: Ology, MaxCyte make moves in women’s cancer with divergent approval chances

Features

Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir

Features

Akebia and GSK will grapple with heightened scrutiny of HIF PHIs after roxadustat concerns

Features

Regulatory roundup: Sanofi/Regeneron, J&J and Eyenovia boost approval chances with Phase III updates

Features

Trial of AbbVie’s NASH drug against severe Covid-19 enrols 25% of patients after a year

Features

Regulatory roundup: Servier, Pfizer and Debiopharm gather gains with oncology trial updates; Karyopharm poses a loss

Features

After Covid-19, mRNA technology aims to revolutionise the flu shot

Features

Pepaxto’s US uptake to stall in multiple myeloma until FDA provides advice to address death risk

Reynald Castañeda

Features

Medicare’s National Coverage Determination could boost chances of limited Aduhelm coverage despite backlash

Comment

Roche’s Evrysdi is a strong contender for SMA market share following EMA nod

GlobalData Healthcare

Comment

Another domestic Chinese PD-1 inhibitor enters the race for US approval following Coherus BioSciences’ deal with Shanghai Junshi Biosciences

GlobalData Healthcare

Comment

Roche’s Ocrevus set to top $7.6bn in sales by 2028 backed by new dosing approval

GlobalData Healthcare

Comment

ASH20: uniQure presents strong data for its gene therapy EtranaDez in haemophilia B patients, aims for BLA in 2021

GlobalData Healthcare

Features

Top ten pharma companies in 2020